


Licensing Options



How to license ddRNAi



Our gene silencing platform technology can be licensed to develop therapies for multiple human diseases including cancers, neurological diseases, infectious diseases, autoimmune diseases and many other diseases and conditions. Target-specific exclusive and non-exclusive licenses are available for a broad range of gene targets. [Contact Us](#)

License our in-house pipeline programs

Benitec Biopharma operates a virtual model, conducting in-house therapeutic programs by outsourcing strategic components of our research and development. We have selected several key human conditions which can demonstrate the efficacy and safety of ddRNAi - including hepatitis C, hepatitis B, drug resistant lung cancer, wet Age-related Macular Degeneration and more. These conditions all have viable delivery options, high commercial potential and realistic regulatory pathways.

Our plan is to progress our in-house therapeutic programs to proof of concept studies, Phase I and II trials before seeking to license the programs to pharmaceutical companies. [Contact Us](#)

Partner and/or co-develop

We also invite opportunities to leverage our ddRNAi platform technology for a wide range of therapeutics, via joint ventures with biotech and pharma companies.

Co-development inquiries are welcomed from groups with an interest in taking an early option on one or more of our in-house programs. [Contact Us](#)

Access our research tools

We are also monetizing ddRNAi technology in the form of research tools which are available through technology licensing. [Contact Us](#)

PIPELINE

- | In-house Programs
- | Licensed Programs
- | Licensing Options
- | Partners

Receive Updates via Email

Keep up with programs, analyst reports, announcements, events and more. Choose what you want.

YES PLEASE

Contact Us

Ask about our technology, licensing, partnering and more. Call or email us.

YES PLEASE

TECHNOLOGY
 What is ddRNAi?
 What is RNAi?
 siRNA vs shRNA
 Publications
 Science Glossary

INTELLECTUAL PROPERTY
 Overview
 Benitec Patents
 Licensed Patents
 Trademarks

PIPELINE
 In-house programs
 Licensed programs
 Licensing options
 Partners

ABOUT US
 Our story
 Management
 Board
 Corporate Directory

INVESTOR CENTRE
 Why Invest in Benitec?
 Stock Info
 ASX Announcements
 Email Updates
 Presentations
 Analyst Coverage
 Reports
 Investor Fact Sheet
 Shareholder Meetings
 Investor FAQ
 ADR Trading